Published in DNA Cell Biol on March 01, 2003
Transforming growth factor-β-inducible early response gene 1 is a novel substrate for atypical protein kinase Cs. Cell Mol Life Sci (2010) 0.76
Discovery of small molecule inhibitors to Krüppel-like factor 10 (KLF10): implications for modulation of T regulatory cell differentiation. J Med Chem (2015) 0.76
Cabut/dTIEG associates with the transcription factor Yorkie for growth control. EMBO Rep (2015) 0.75
Effect of dutasteride on the risk of prostate cancer. N Engl J Med (2010) 12.78
DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med (2006) 7.90
Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res (2008) 6.33
Dynamic FoxO transcription factors. J Cell Sci (2007) 6.30
Mechanisms of androgen-refractory prostate cancer. N Engl J Med (2004) 4.49
Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev (2007) 3.54
CDK2-dependent phosphorylation of FOXO1 as an apoptotic response to DNA damage. Science (2006) 3.41
Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res (2002) 3.26
Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. Proc Natl Acad Sci U S A (2005) 3.16
Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J Clin Oncol (2011) 2.99
Plk1-dependent phosphorylation of FoxM1 regulates a transcriptional programme required for mitotic progression. Nat Cell Biol (2008) 2.68
Androgen receptor structural and functional elements: role and regulation in prostate cancer. Mol Endocrinol (2007) 2.53
Alternatively spliced androgen receptor variants. Endocr Relat Cancer (2011) 2.41
Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet (2003) 1.96
Androgen receptor signaling in prostate cancer development and progression. J Carcinog (2011) 1.90
Molecular regulation of androgen action in prostate cancer. J Cell Biochem (2006) 1.81
Hypermethylation of genes for diagnosis and risk stratification of prostate cancer. Cancer Invest (2009) 1.64
Regulation of FOXO protein stability via ubiquitination and proteasome degradation. Biochim Biophys Acta (2011) 1.52
p300 in prostate cancer proliferation and progression. Cancer Res (2003) 1.50
Androgen regulation of gene expression. Adv Cancer Res (2010) 1.47
Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer. Eur Urol (2007) 1.44
Ligand-independent androgen receptor activity is activation function-2-independent and resistant to antiandrogens in androgen refractory prostate cancer cells. J Biol Chem (2006) 1.43
Minireview: Alternative activation pathways for the androgen receptor in prostate cancer. Mol Endocrinol (2011) 1.43
New developments in the medical management of prostate cancer. Mayo Clin Proc (2010) 1.41
Induction of prostatic intraepithelial neoplasia and modulation of androgen receptor by ETS variant 1/ETS-related protein 81. Cancer Res (2009) 1.39
FOXO factors: a matter of life and death. Future Oncol (2006) 1.35
Selective role of an NH2-terminal WxxLF motif for aberrant androgen receptor activation in androgen depletion independent prostate cancer cells. Cancer Res (2007) 1.34
Global methylation profiling for risk prediction of prostate cancer. Clin Cancer Res (2012) 1.30
p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. Cancer Res (2002) 1.29
FAVL elevation in human tumors disrupts Fanconi anemia pathway signaling and promotes genomic instability and tumor growth. J Clin Invest (2010) 1.25
Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter. Mol Ther (2009) 1.22
Regulation of androgen receptor signaling in prostate cancer. Expert Rev Anticancer Ther (2005) 1.21
Androgens negatively regulate forkhead transcription factor FKHR (FOXO1) through a proteolytic mechanism in prostate cancer cells. J Biol Chem (2004) 1.20
Androgen induction of the androgen receptor coactivator four and a half LIM domain protein-2: evidence for a role for serum response factor in prostate cancer. Cancer Res (2007) 1.19
The role of androgens and the androgen receptor in prostate cancer. Cancer Lett (2002) 1.18
RhoA as a mediator of clinically relevant androgen action in prostate cancer cells. Mol Endocrinol (2012) 1.16
Posttranslational modification of the androgen receptor in prostate cancer. Int J Mol Sci (2013) 1.16
Vascular endothelial growth factor-C protects prostate cancer cells from oxidative stress by the activation of mammalian target of rapamycin complex-2 and AKT-1. Cancer Res (2009) 1.15
Androgen modulation of coregulator expression in prostate cancer cells. Mol Endocrinol (2009) 1.14
PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer. Clin Cancer Res (2006) 1.13
Androgen deprivation increases p300 expression in prostate cancer cells. Cancer Res (2007) 1.12
p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6. Cancer Res (2005) 1.10
Inhibition of fatty acid synthase activity in prostate cancer cells by dutasteride. Prostate (2007) 1.09
TGF-betal/Smad signaling in prostate cancer. Curr Drug Targets (2003) 1.08
The role of the androgen receptor in prostate cancer. Crit Rev Eukaryot Gene Expr (2002) 1.08
Targeting 5α-reductase for prostate cancer prevention and treatment. Nat Rev Urol (2011) 1.06
Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder. Endocr Relat Cancer (2008) 1.06
p300 modulates nuclear morphology in prostate cancer. Cancer Res (2005) 1.04
Oxidative stress and DNA methylation in prostate cancer. Obstet Gynecol Int (2010) 1.03
Gene silencing for epidermal growth factor receptor variant III induces cell-specific cytotoxicity. Mol Cancer Ther (2008) 0.99
Androgen receptor abnormalities in castration-recurrent prostate cancer. Expert Rev Endocrinol Metab (2009) 0.97
The cytoskeleton differentially localizes the early growth response gene-1 protein in cancer and benign cells of the prostate. Mol Cancer Res (2004) 0.96
Autophagy control by the VEGF-C/NRP-2 axis in cancer and its implication for treatment resistance. Cancer Res (2012) 0.95
Androgens and prostate cancer: are the descriptors valid? Cancer Biol Ther (2005) 0.95
Identification of a clinically relevant androgen-dependent gene signature in prostate cancer. Cancer Res (2011) 0.94
Androgen receptor: past, present and future. Curr Drug Targets (2013) 0.92
Loss of NKX3.1 favors vascular endothelial growth factor-C expression in prostate cancer. Cancer Res (2008) 0.92
Androgens repress Bcl-2 expression via activation of the retinoblastoma (RB) protein in prostate cancer cells. Oncogene (2004) 0.92
Mechanism of lymph node metastasis in prostate cancer. Future Oncol (2010) 0.90
Reduced tumor necrosis factor receptor-associated death domain expression is associated with prostate cancer progression. Cancer Res (2009) 0.90
Novel molecular targets of Azadirachta indica associated with inhibition of tumor growth in prostate cancer. AAPS J (2011) 0.89
Unraveling the complexities of androgen receptor signaling in prostate cancer cells. Cancer Cell (2009) 0.88
CBP loss cooperates with PTEN haploinsufficiency to drive prostate cancer: implications for epigenetic therapy. Cancer Res (2014) 0.88
Gene expression in prostate cancer cells treated with the dual 5 alpha-reductase inhibitor dutasteride. J Androl (2004) 0.88
Differential regulation of steroid nuclear receptor coregulator expression between normal and neoplastic prostate epithelial cells. Prostate (2010) 0.87
Truncating variants in p53AIP1 disrupting DNA damage-induced apoptosis are associated with prostate cancer risk. Cancer Res (2006) 0.86
Androgens repress expression of the F-box protein Skp2 via p107 dependent and independent mechanisms in LNCaP prostate cancer cells. Prostate (2011) 0.86
Androgen action in prostate cancer. Horm Cancer (2010) 0.85
Deficiencies in Chfr and Mlh1 synergistically enhance tumor susceptibility in mice. J Clin Invest (2009) 0.85
Regulation of expression of the early growth response gene-1 (EGR-1) in malignant and benign cells of the prostate. Prostate (2005) 0.84
Prostate cancer cells use genetic and epigenetic mechanisms for progression to androgen independence. Genes Chromosomes Cancer (2006) 0.84
Effects of the 5 alpha-reductase inhibitor dutasteride on gene expression in prostate cancer xenografts. Prostate (2009) 0.84
Steroid 5 α-reductase inhibitors targeting BPH and prostate cancer. J Steroid Biochem Mol Biol (2010) 0.83
The role of the transcriptional coactivator p300 in prostate cancer progression. Adv Exp Med Biol (2008) 0.83
Androgen action during prostate carcinogenesis. Methods Mol Biol (2011) 0.83
Unique substitution of CHEK2 and TP53 mutations implicated in primary prostate tumors and cancer cell lines. Hum Mutat (2006) 0.82
CDK2 and FOXO1: a fork in the road for cell fate decisions. Cell Cycle (2007) 0.82
Gluthatione-S-transferase P1 polymorphism I105V in familial and sporadic prostate cancer. Cancer Genet Cytogenet (2004) 0.82
Induction of FLIP expression by androgens protects prostate cancer cells from TRAIL-mediated apoptosis. Prostate (2008) 0.82
Androgens regulate TRAIL-induced cell death in prostate cancer cells via multiple mechanisms. Cancer Lett (2013) 0.80
Inverse association between prostate cancer and the use of calcium channel blockers. Cancer Epidemiol Biomarkers Prev (2004) 0.78
Antiangiogenic Effects and Therapeutic Targets of Azadirachta indica Leaf Extract in Endothelial Cells. Evid Based Complement Alternat Med (2012) 0.78
Preclinical evaluation of the supercritical extract of azadirachta indica (neem) leaves in vitro and in vivo on inhibition of prostate cancer tumor growth. Mol Cancer Ther (2014) 0.77
Of mice, men, and hormones. Arterioscler Thromb Vasc Biol (2004) 0.76
Dihydrotestosterone synthesis from adrenal precursors does not involve testosterone in castration-resistant prostate cancer. Cancer Biol Ther (2012) 0.76
Transformation of NIH 3T3 cells by enhanced PAR expression. Biochem Biophys Res Commun (2004) 0.75
Evaluation of familial clustering of breast and prostate cancer in the Minnesota Breast Cancer Family Study. Cancer Detect Prev (2003) 0.75
Decline in the overall incidence of regional-distant prostate cancer in Olmsted County, MN, 1980-2000. BJU Int (2005) 0.75